In a webinar hosted by the Petrie-Flom Center for Health Law Policy of the Harvard Law School, speakers championed for psychedelics decriminalization. The webinar, which gathered more than 200 individuals, had panelists who discussed the benefits of the decriminalization of psychedelics while debating on the history and safety of the substances and how they affected people of color.
The webinar’s moderator, Mason Marks, is a law professor at Gonzaga University. The speakers featured on the webinar included Patricia J. Zettler, associate professor at the Ohio State Moritz College of Law; Ifetayo Harvey, founder of the People of Color Psychedelic Collective; Dustin Marlan, assistant professor at the University of Massachusetts School of Law; and Larissa J. Maier, a postdoctoral scholar at the University of California San Francisco School of Pharmacy.
Marlan explained that individuals should be allowed to use psychedelics as long as their use does not affect or injure other individuals. Additionally, some speakers also advocated for the decriminalization of all drugs. Maier voiced her views on the issue, stating that no individual needed to be criminalized for the possession or use of a limited amount of drugs.
The speakers also traced drug prohibition in the United States back to the 1970s, asserting that prohibition efforts weren’t entrenched in drug-use prevention but in progressive social group disorganization. Harvey explained that the 1960s and 1970s had many movements, such as the anti-war movement and the civil rights movement, which explained the need to disrupt them.
According to the panelists, in addition to causing disruption these efforts also impeded research that may have revealed the possible uses of psychedelic substances in the medical field.
Maier explained that in the 1970s, more than 1,000 promising reports had been published that showed systematic reviews of the safety and effectiveness of LSD as a treatment for various mental health conditions.
Things are looking up though, after voters from the District of Columbia decriminalized psilocybin mushrooms and other psychedelic substances. In addition, the state of Oregon became the first state in the country to legalize psilocybin during the elections held three weeks ago.
Despite all panelists agreeing on the decriminalization of most drugs, some speakers expressed their concerns regarding such policies. Zettler and Harvey remarked that decriminalization could decrease drug use stigma but it could also foster a false sense of security for individuals who are not knowledgeable about laws concerning drug distribution and use.
Zettler added that it would be important to conduct research that looks into the effectiveness and safety of psychedelics before their use was legalized for the masses. This would help society understand the effects of these substances in detail.
The evolving regulatory landscape has allowed a number of companies to mushroom in the functional mushrooms space. For instance, Cybin Inc. (NEO: CYBN) is focused on developing fungi-based medications as well as functional wellness products.
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
